Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY4152199 - IV
LY4152199 · 1 trial · 7 indications
| Arm | Type | Description |
|---|---|---|
| Phase 1: Dose Escalation (Cohort A) - DLBCL and FL | EXPERIMENTAL | Escalating doses of LY4152199 administered intravenously (IV) |
| Phase 1: Dose Optimization (Cohort B1) - DLBCL | EXPERIMENTAL | Two or more doses of LY4152199 (evaluated during dose escalation) administered IV |
| Phase 1: Dose Optimization (Cohort B2) - FL | EXPERIMENTAL | Two or more doses of LY4152199 (evaluated during dose escalation) administered IV |
| Name | Type | Description |
|---|---|---|
| LY4152199 - IV | DRUG | Administered by IV infusion |
Inclusion Criteria: * Must have a diagnosis of either follicular lymphoma or diffuse large B-cell lymphoma. * Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Estimated life expectancy of greater than or equal to (≥)12 weeks as judged by the Investigator. * Par...
LY4152199 is an investigational small molecule being developed for the treatment of non-Hodgkin lymphoma, including B-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, Waldenstrom macroglobulinemia, and mantle cell lymphoma. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
LY4152199 targets BAFF-R, a receptor involved in B-cell survival and maturation. By modulating this receptor, the drug is designed to address B-cell malignancies such as non-Hodgkin lymphoma. The drug is a small molecule, and its mechanism of action is being evaluated in early-stage clinical trials.
LY4152199 is being developed by Eli Lilly and Company, a biopharmaceutical company listed on the stock exchange under the ticker LLY. The company is conducting a Phase 1 clinical trial to evaluate the drug in participants with previously treated B-cell malignancies.
LY4152199 is in Phase 1 clinical development. It is an investigational drug and has not received regulatory approval. The drug is being studied in a Phase 1 trial that is currently recruiting participants with previously treated B-cell malignancies, including various types of non-Hodgkin lymphoma.
LY4152199 is being evaluated in a Phase 1 clinical trial with the identifier NCT07101328, titled 'A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1)'. This trial is actively recruiting up to 215 participants across multiple countries, including the United States, Australia, Canada, and several European and Asian nations.
Yes, LY4152199 is also known as LY4152199 - IV, which refers to the intravenous formulation of the drug. This alternative name is used in clinical contexts to specify the route of administration. The drug is being studied in an intravenous form in the ongoing Phase 1 trial for non-Hodgkin lymphoma.